222 related articles for article (PubMed ID: 23206263)
1. Evaluating risks, costs, and benefits of new and emerging therapies to optimize outcomes in multiple sclerosis.
Bandari DS; Sternaman D; Chan T; Prostko CR; Sapir T
J Manag Care Pharm; 2012; 18(9):1-17. PubMed ID: 23206263
[TBL] [Abstract][Full Text] [Related]
2. Incorporating the treat-to-target concept in rheumatoid arthritis.
Ruderman EM; Nola KM; Ferrell S; Sapir T; Cameron DR
J Manag Care Pharm; 2012; 18(9):1-18. PubMed ID: 23206239
[TBL] [Abstract][Full Text] [Related]
3. Managed approaches to multiple sclerosis in special populations.
Sperandeo K; Nogrady L; Moreo K; Prostko CR
J Manag Care Pharm; 2011; 17(9 Suppl C):S1-19; quiz S20-1. PubMed ID: 22107156
[TBL] [Abstract][Full Text] [Related]
4. New Therapies, Evidence, and Guidance in Hepatitis C Management: Expert Practices and Insights from an Educational Symposium at the AMCP 27th Annual Meeting Expo.
Terrault N; Monto A; Stinchon MR; Rusie E; Moreo K
J Manag Care Spec Pharm; 2015 Sep; 21(9):S1-14. PubMed ID: 26308363
[TBL] [Abstract][Full Text] [Related]
5. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E;
J Clin Neurosci; 2014 Nov; 21(11):1847-56. PubMed ID: 24986155
[TBL] [Abstract][Full Text] [Related]
7. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
8. Current and future directions in MS management: key considerations for managed care pharmacists.
Lipsy RJ; Schapiro RT; Prostko CR
J Manag Care Pharm; 2009; 15(9 Suppl A):S2-15; quiz S16-7. PubMed ID: 19877743
[TBL] [Abstract][Full Text] [Related]
9. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
10. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
[TBL] [Abstract][Full Text] [Related]
11. Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies.
Owens GM; Olvey EL; Skrepnek GH; Pill MW
J Manag Care Pharm; 2013; 19(1 Suppl A):S41-53. PubMed ID: 23383732
[TBL] [Abstract][Full Text] [Related]
12. Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management.
Stuart WH
J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S19-25. PubMed ID: 15253686
[TBL] [Abstract][Full Text] [Related]
13. The fiscal consequences of public health investments in disease-modifying therapies for the treatment of multiple sclerosis in Sweden.
Kotsopoulos N; Connolly MP; Dort T; Kavaliunas A
J Med Econ; 2020 Aug; 23(8):831-837. PubMed ID: 32400258
[No Abstract] [Full Text] [Related]
14. One-Year Outcomes of an Integrated Multiple Sclerosis Disease Management Program.
Groeneweg M; Forrester SH; Arnold B; Palazzo L; Zhu W; Yoon P; Scearce T
J Manag Care Spec Pharm; 2018 May; 24(5):458-463. PubMed ID: 29694287
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
16. Economic burden of multiple sclerosis and the role of managed sare organizations in multiple sclerosis management.
Owens GM
Am J Manag Care; 2016 Jun; 22(6 Suppl):s151-8. PubMed ID: 27356024
[TBL] [Abstract][Full Text] [Related]
17. Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.
Watkins JB; Minshall ME; Sullivan SD
J Manag Care Pharm; 2006; 12(9):726-35. PubMed ID: 17249905
[TBL] [Abstract][Full Text] [Related]
18. Established and novel disease-modifying treatments in multiple sclerosis.
Cross AH; Naismith RT
J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
[TBL] [Abstract][Full Text] [Related]
19. Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).
Jongen PJ; Hengstman G; Hupperts R; Schrijver H; Gilhuis J; Vliegen JH; Hoogervorst E; van Huizen M; van Munster E; Samijn J; de Schryver E; Siepman T; Tonk M; Zandbergen E; ten Holter J; van der Kruijk R; Borm G
BMC Neurol; 2011 Mar; 11():40. PubMed ID: 21450086
[TBL] [Abstract][Full Text] [Related]
20. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.
Menzin J; Caon C; Nichols C; White LA; Friedman M; Pill MW
J Manag Care Pharm; 2013; 19(1 Suppl A):S24-40. PubMed ID: 23383731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
